Skip to main content

Advertisement

SpringerLink
Log in

Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The transmembrane transport of anticancer drugs is mainly regulated by P-glycoprotein encoded by the human multidrug resistance gene 1 gene (MDR1). Since there were controversies regarding the association between MDR1 C3435T polymorphism and response to chemotherapy among patients with advanced breast cancer, a meta-analysis of the link was conducted. A total of 7 studies consist of 464 advanced breast cancer patients relating MDR1 C3435T polymorphism to the response of chemotherapy were included in this meta-analysis. The main analysis revealed a lack of association between the MDR1 C3435T and response to chemotherapy, with odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of 1.37 (95% CI: 0.78–2.40), 1.17 (95% CI: 0.69–2.01), 1.18 (95% CI: 0.76–1.84) and 1.61 (95% CI: 0.70–3.68) for homozygous comparison, heterozygous comparison, dominant model and recessive model, respectively. The subgroup analysis by ethnicity did not change the pattern of results, with ORs of 0.99 (95% CI: 0.11–9.07), 0.68 (95% CI: 0.29–1.60), 0.81 (95% CI: 0.36–1.85) and 1.51 (95% CI: 0.77–2.96), in homozygous comparison, heterozygous comparison, dominant model and recessive model, respectively in Caucasian, and 1.50 (95% CI: 0.75–3.03), 1.72 (95% CI: 0.85–3.47), 1.59 (95% CI: 0.90–2.80) and 2.29 (95% CI: 0.51–10.35), respectively in Asian. The available evidence indicates that MDR1 C3435T polymorphism cannot be considered as a reliable predictor of response to chemotherapy in patients with advanced breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

    Article  PubMed  Google Scholar 

  3. Fan L, Zheng Y, Yu KD et al (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409–416

    Article  PubMed  Google Scholar 

  4. Gor PP, Su HI, Gray RJ et al (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12:R26

    Article  PubMed  Google Scholar 

  5. Breier A, Barancik M, Sulova Z et al (2005) P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5:457–468

    Article  PubMed  CAS  Google Scholar 

  6. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    Article  PubMed  CAS  Google Scholar 

  7. Soto-Vega E, Arroyo C, Richaud-Patin Y et al (2009) P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol 27:363–366

    Article  PubMed  CAS  Google Scholar 

  8. Vlachogeorgos GS, Manali ED, Blana E et al (2008) Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival. Cancer 114:519–526

    Article  PubMed  CAS  Google Scholar 

  9. Gouaze V, Yu JY, Bleicher RJ et al (2004) Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3:633–639

    PubMed  CAS  Google Scholar 

  10. Burger H, Foekens JA, Look MP et al (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 9:827–836

    PubMed  CAS  Google Scholar 

  11. Mutoh K, Tsukahara S, Mitsuhashi J et al (2006) Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 97:1198–1204

    Article  PubMed  CAS  Google Scholar 

  12. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  PubMed  CAS  Google Scholar 

  13. Nauck M, Stein U, von Karger S et al (2000) Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 46:1995–1997

    PubMed  CAS  Google Scholar 

  14. Tahara T, Arisawa T, Shibata T et al (2007) Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 22:1678–1682

    Article  PubMed  CAS  Google Scholar 

  15. Maffioli M, Camos M, Gaya A et al (2010) Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 35:1014–1019

    Article  PubMed  Google Scholar 

  16. Ni LN, Li JY, Miao KR et al (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265–269

    Article  PubMed  CAS  Google Scholar 

  17. Kafka A, Sauer G, Jaeger C et al (2003) Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117–1121

    PubMed  CAS  Google Scholar 

  18. Ashariati A (2008) Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones 40:187–191

    PubMed  Google Scholar 

  19. Cizmarikova M, Wagnerova M, Schonova L et al (2010) MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10:62–69

    Article  PubMed  CAS  Google Scholar 

  20. Zhang BL, Sun T, Zhang BN et al (2011) Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl) 124:199–204

    CAS  Google Scholar 

  21. Cochran W (1954) The combination of estimates from different experiments. Biometrics 10:101–129

    Article  Google Scholar 

  22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

    Article  PubMed  Google Scholar 

  24. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  25. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  PubMed  CAS  Google Scholar 

  26. George J, Dharanipragada K, Krishnamachari S et al (2009) A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 9:161–165

    Article  PubMed  CAS  Google Scholar 

  27. George J, Dharanipragada K, Krishnamachari S et al (2009) Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272–277

    Google Scholar 

  28. Rodrigues FF, Santos RE, Melo MB et al (2008) Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 7:177–183

    Article  PubMed  CAS  Google Scholar 

  29. Zintzaras E, Ziogas DC, Kitsios GD et al (2009) MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics 10:1285–1294

    Article  PubMed  CAS  Google Scholar 

  30. Verrelle P, Meissonnier F, Fonck Y et al (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116

    Article  PubMed  CAS  Google Scholar 

  31. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73

    Article  PubMed  CAS  Google Scholar 

  32. Chevillard S, Lebeau J, Pouillart P et al (1997) Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471–2478

    PubMed  CAS  Google Scholar 

  33. Tanabe M, Ieiri I, Nagata N et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143

    PubMed  CAS  Google Scholar 

  34. Levine MN, Whelan T (2006) Adjuvant chemotherapy for breast cancer—30 years later. N Engl J Med 355:1920–1922

    Article  PubMed  CAS  Google Scholar 

  35. Merk J, Rolff J, Dorn C et al (2011) Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 40:e29–e33

    Article  PubMed  Google Scholar 

  36. Moureau-Zabotto L, Ricci S, Lefranc JP et al (2006) Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94:473–480

    Article  PubMed  CAS  Google Scholar 

  37. Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285–307

    Article  PubMed  CAS  Google Scholar 

  38. Illmer T, Schuler US, Thiede C et al (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955–4962

    PubMed  CAS  Google Scholar 

  39. Sohn JW, Lee SY, Lee SJ et al (2006) MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 36:137–141

    Article  PubMed  Google Scholar 

  40. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–1203

    Article  PubMed  CAS  Google Scholar 

  41. Jiko M, Yano I, Sato E et al (2007) Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 12:284–290

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

 There is no conflict of interests.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The Second Affiliated Hospital, and Cancer Institute, Zhejiang University School of Medicine, Hangzhou, 310009, China

    Guodi Chen, Qiongge Hu & Liancong Wang

  2. Department of Clinical Medicine, Zhejiang University City College, Hangzhou, 310015, China

    Sheng Quan

  3. Clinical Laboratory of Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310016, China

    Xiaoping Xia

  4. Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Jing Wu

Authors
  1. Guodi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiongge Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liancong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoping Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaoping Xia or Jing Wu.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, G., Quan, S., Hu, Q. et al. Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies. Mol Biol Rep 39, 5161–5168 (2012). https://doi.org/10.1007/s11033-011-1312-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-011-1312-2

Keywords

Search

Navigation